| Philip J Fischer Ii, MD | |
|
800 St Vincents Dr, Suite 630, Birmingham, AL 35205 | |
| (205) 939-6888 | |
| (205) 939-6897 |
| Full Name | Philip J Fischer Ii |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 27 Years |
| Location | 800 St Vincents Dr, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821163585 | NPI | - | NPPES |
| P00012864 | Other | MEDICARE TRAVELERS | |
| 5595491 | Other | FIRST HEALTH | |
| 51526308 | Other | AL | BLUE CROSS |
| 7727323 | Other | AL | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 00021924 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Vincent's Birmingham | Birmingham, AL | Hospital |
| Brookwood Baptist Medical Center | Birmingham, AL | Hospital |
| Entity Name | Philip J. Fischer, Ii, M.d.,p.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275733842 PECOS PAC ID: 1759335565 Enrollment ID: O20050304000151 |
News Archive
Reata Pharmaceuticals today announced that the company will present data on the primary endpoint from a pivotal Phase 2b clinical trial of bardoxolone methyl in patients with chronic kidney disease (CKD) and type 2 diabetes. The data will be presented in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference to be held November 16-21, 2010, in Denver, Colorado.
The U.S. Food and Drug Administration today approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for the transmucosal immediate-release fentanyl (TIRF) products. This new shared system will replace the individual REMS and allow prescribers and pharmacies to enroll into just one system, easing the burden on the health care system.
Psychological therapy plus medication appears to be the most effective treatment strategy for chronic migraine in children, but it may take time for the medical system to widely adopt this approach, says an editorial in the current issue of the Journal of the American Medical Association by Mark Connelly, PhD, a pain psychologist and co-director of the Comprehensive Headache Clinic at Children's Mercy Hospital.
Cabazitaxel has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Philip J Fischer Ii, MD Post Office Box 130250, Birmingham, AL 35213-0250 Ph: (205) 939-6888 | Philip J Fischer Ii, MD 800 St Vincents Dr, Suite 630, Birmingham, AL 35205 Ph: (205) 939-6888 |
News Archive
Reata Pharmaceuticals today announced that the company will present data on the primary endpoint from a pivotal Phase 2b clinical trial of bardoxolone methyl in patients with chronic kidney disease (CKD) and type 2 diabetes. The data will be presented in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference to be held November 16-21, 2010, in Denver, Colorado.
The U.S. Food and Drug Administration today approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for the transmucosal immediate-release fentanyl (TIRF) products. This new shared system will replace the individual REMS and allow prescribers and pharmacies to enroll into just one system, easing the burden on the health care system.
Psychological therapy plus medication appears to be the most effective treatment strategy for chronic migraine in children, but it may take time for the medical system to widely adopt this approach, says an editorial in the current issue of the Journal of the American Medical Association by Mark Connelly, PhD, a pain psychologist and co-director of the Comprehensive Headache Clinic at Children's Mercy Hospital.
Cabazitaxel has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel.
› Verified 5 days ago
Melanie Morris, Surgery Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Rebecca Horst, PA Surgery Medicare: Medicare Enrolled Practice Location: 817 Princeton Ave Sw Ste 306, Birmingham, AL 35211 Phone: 205-783-0160 Fax: 205-788-6249 | |
Timothy Lee Christopher, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3686 Grandview Pkwy Ste 400, Birmingham, AL 35243 Phone: 205-595-8985 Fax: 205-595-8987 | |
Dr. Richard Ira Kirkland, MD Surgery Medicare: Medicare Enrolled Practice Location: 513 Brookwood Blvd, Suite 501, Birmingham, AL 35209 Phone: 205-930-8010 Fax: 205-930-8014 | |
Kyle Stigall, MD Surgery Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35233 Phone: 205-934-4011 | |
Jayme Locke, Surgery Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Emily Long, MD Surgery Medicare: Medicare Enrolled Practice Location: 50 Medical Park Dr E, Birmingham, AL 35235 Phone: 205-838-3000 |